Research Context Only. SR-17018 is a Schedule I research compound not approved for human or veterinary use. The dose ranges discussed in this article are derived from preclinical pharmacology literature and are presented for scientific research reference only. Nothing here constitutes medical advice or a dosing recommendation for human subjects.
Why SR-17018 Dosing Requires a Different Framework Than Full Agonists
The conventional approach to opioid dosing uses morphine milligram equivalents (MME) as a reference currency — expressing the potency of a compound relative to morphine. This system works reasonably well for full agonists that differ primarily in their binding affinity and pharmacokinetics. It breaks down when applied to biased agonists like SR-17018.
The reason is signal transduction. SR-17018 preferentially activates the G-protein (Gi/o) pathway over the beta-arrestin 2 recruitment pathway at the mu-opioid receptor — a property called functional selectivity or G-protein bias. The behavioral and physiological consequences of this signaling difference mean that SR-17018 produces different effects at the same receptor occupancy compared to a non-biased full agonist. In particular, it shows substantially reduced tolerance development and a shallower dose-response slope for certain effects.
This means that doses derived by scaling from morphine equivalents may significantly overestimate the amount of SR-17018 needed for equivalent receptor engagement. Starting from the pharmacology — Ki, EC₅₀, and in vivo dose-response data — rather than from MME conversion is a more principled approach.
Key Pharmacological Parameters from the Literature
The following parameters are derived from published preclinical pharmacology studies (primarily Yudin et al., 2019; Kliewer et al., 2019; and the Traynor lab series at University of Michigan). They describe SR-17018's binding characteristics and functional activity at the human and murine mu-opioid receptor.
| Parameter | SR-17018 | Morphine (reference) | Significance |
|---|---|---|---|
| MOR binding Ki | ~0.76 nM | ~1.8 nM | SR-17018 has ~2× higher receptor affinity than morphine |
| G-protein EC₅₀ (BRET) | ~3–8 nM | ~15–30 nM | More potent G-protein activator than morphine on a molar basis |
| Beta-arrestin 2 EC₅₀ | Weak / partial | Full recruitment | Markedly reduced arrestin signaling — key to tolerance profile |
| G-protein efficacy (Emax) | ~70–80% of DAMGO | ~60–70% of DAMGO | Moderate to high intrinsic G-protein efficacy |
| Tolerance ratio (chronic vs acute) | ~2–3× | ~8–12× | Substantially less tolerance development after chronic dosing |
| Antinociceptive ED₅₀ (mice, i.p.) | ~3–10 mg/kg | ~6–10 mg/kg | Comparable analgesic potency to morphine in vivo |
Values represent ranges across published assay systems. Preclinical rodent data; human pharmacokinetics are not established. Ki values from radioligand binding assays (³H-DAMGO competition). BRET = bioluminescence resonance energy transfer.
Variables That Affect Effective Research Dose
No single dose works for every research context. The following variables have the largest impact on what dose produces the target effect in a given experimental design:
Subjects with established mu-opioid receptor tolerance (from prior opioid, kratom, or 7-OH exposure) will require higher doses for equivalent receptor occupancy. SR-17018's low tolerance ceiling means its own prior use minimally affects this variable, but prior full-agonist exposure dramatically raises the starting dose requirement. This is the single most important variable in clinical research translation.
Preclinical in vivo dosing is expressed per kg of body weight. While human pharmacokinetics aren't directly calculable from rodent data, body weight scales the total receptor pool and volume of distribution. Heavier subjects may require proportionally higher doses.
Intraperitoneal (i.p.) dosing in rodents has ~100% bioavailability compared to oral gavage (~30–60% depending on formulation). The volumetric solution is formulated for oral research use; bioavailability assumptions derived from i.p. preclinical data will overestimate the equivalent oral dose.
Different endpoints require different receptor occupancy thresholds. Withdrawal symptom suppression in opioid-dependent subjects may require higher occupancy than analgesic studies in opioid-naive subjects. Taper research focuses on gradual dose reduction rather than a fixed effective dose.
SR-17018 is metabolized via CYP3A4 and CYP2D6. Rapid metabolizers clear it faster; slow metabolizers accumulate it at lower doses. Enzyme inhibitors (e.g., grapefruit, ketoconazole) can substantially increase plasma exposure.
Other mu-opioid agonists, antagonists, or compounds that affect CYP3A4/2D6 can significantly alter effective dose. G-protein biased compounds show altered interaction profiles with naloxone/naltrexone compared to full agonists.
Starting Dose Framework: Low, Moderate, and High Range
Based on published preclinical data and the pharmacokinetic scaling considerations above, researchers have characterized three broad dose ranges for SR-17018 in human-context taper and withdrawal research. These ranges are indicative, not prescriptive — individual protocols should be designed based on specific experimental endpoints and subject tolerance state.
Important: The dose ranges below are derived from allometric scaling of rodent in vivo data and community-reported observational data, not from controlled human clinical trials. They should be treated as a rough starting framework, not confirmed human pharmacology.
| Range | Dose | Solution Volume (10 mg/mL) | Typical Research Context |
|---|---|---|---|
| Micro / Exploratory | 1–5 mg | 0.1–0.5 mL | Opioid-naive subjects; receptor mapping studies; final taper steps |
| Low | 5–15 mg | 0.5–1.5 mL | Low-tolerance subjects; kratom users transitioning off low-dose use; post-taper maintenance research |
| Moderate | 15–35 mg | 1.5–3.5 mL | Moderate opioid/kratom tolerance; established 7-OH dependence; initial substitution research |
| High | 35–75 mg | 3.5–7.5 mL | High opioid tolerance subjects; OUD research; heavy kratom (7-OH) dependence; initial stabilization |
| Very High | 75–150 mg | 7.5–15 mL | Severe OUD research; methadone/buprenorphine-equivalent tolerance contexts; use with caution |
For a given taper target, start conservatively and titrate up based on observed response. SR-17018's ceiling effect (diminishing returns on G-protein signaling at high doses) means that doses above 75 mg typically provide disproportionately less additional effect relative to side-effect risk.
Timing, Frequency, and the Half-Life Question
SR-17018's plasma half-life in rodent models is approximately 1.5–3 hours after intraperitoneal administration. Oral bioavailability in rats ranges from ~30–50%, which would extend effective duration but reduce peak exposure. Human pharmacokinetic data does not exist.
In practice, preclinical studies use dosing intervals of 6–12 hours for sustained effect. For taper research, the goal is typically stable background receptor occupancy rather than peak-and-trough cycling — which argues for more frequent, smaller doses over fewer, larger doses. This is pharmacologically analogous to why methadone's long half-life is considered advantageous for OUD treatment: it eliminates the peaks and troughs that drive craving.
| Dosing Pattern | Pros | Cons |
|---|---|---|
| Single large daily dose | Simpler protocol; easier to track | High peak → trough cycling; may produce withdrawal between doses at shorter half-life |
| Split dose (2×/day) | Smooths plasma curve; reduces peak-trough amplitude; preferred in most protocols | Requires two measurement events per day |
| Three or more doses daily | Maximally stable receptor occupancy; most closely mimics continuous infusion model | Compliance burden; volumetric precision required for each small sub-dose |
The Ceiling Effect: Why Dose Escalation Has Diminishing Returns
One of the defining features of G-protein biased agonists — and SR-17018 specifically — is a pronounced ceiling in the dose-response curve for certain effects. Kliewer et al. (2019) demonstrated that SR-17018 produces a shallower antinociceptive dose-response slope compared to morphine, with a functional ceiling that limits the maximum achievable effect below the 100% Emax seen with full agonists.
This has two practical implications for dosing research:
Doubling the dose does not double the effect
In the upper dose ranges, the marginal benefit of each additional milligram of SR-17018 decreases rapidly. For taper research, this means that dose reductions from high doses may produce less withdrawal symptom change than equivalent percentage reductions in the lower range — the final steps matter more.
The therapeutic window is wide — but the useful window may be narrower
Because dose escalation above the ceiling produces diminishing receptor engagement benefit, very high doses of SR-17018 may not achieve the same degree of withdrawal suppression as equivalent doses of full agonists in highly tolerant subjects. This is an important consideration when designing research protocols for subjects with severe OUD.
From Starting Dose to Taper: A Practical Step-Down Framework
Once a stable starting dose is established, the taper design follows a different logic than a fixed-dose research protocol. The goal is to reduce dose gradually enough that the nervous system can normalize receptor density and signaling without triggering acute withdrawal compensation.
The literature on opioid tapering (from buprenorphine and methadone clinical trials) suggests that reduction rates of 5–10% per week are associated with better completion rates than 20–25% cuts. For SR-17018 taper research, the same principle applies — and volumetric dosing at 10 mg/mL makes these small percentage reductions measurable in practice.
| Starting Dose | 10% Step Size | Volume Step (10 mg/mL) | Approx. Weeks to Zero (10%/wk) |
|---|---|---|---|
| 50 mg | 5 mg | 0.5 mL | ~23 weeks |
| 30 mg | 3 mg | 0.3 mL | ~21 weeks |
| 20 mg | 2 mg | 0.2 mL | ~19 weeks |
| 10 mg | 1 mg | 0.1 mL | ~17 weeks |
| 5 mg | 0.5 mg | 0.05 mL | ~15 weeks |
10% weekly reduction follows a geometric sequence — each step is 10% of the current dose, not 10% of the original dose. This means steps get smaller over time (in absolute mg terms) as the dose decreases, which is physiologically appropriate: the nervous system needs proportionally more time to adapt at lower receptor occupancy levels.
How to Recognize If the Starting Dose Is Correct
In research involving opioid-dependent subjects, three observable outcomes indicate whether an SR-17018 starting dose is within the effective range:
Withdrawal symptom suppression within 30–90 minutes of dosing
Suggests adequate receptor occupancy. If suppression is partial (COWS reduction of 40–60%), dose may be at the low end of the effective range.
No acute opioid-like intoxication or sedation at rest
Expected finding due to G-protein bias and ceiling effect. SR-17018 should not produce pronounced sedation at research doses even in opioid-naive subjects. Its absence is not an indicator of insufficient dose.
Return of withdrawal symptoms before the next dose interval
Indicates the dose may be insufficient OR the dosing interval is too long relative to the half-life. Try splitting the dose into two administrations before increasing total daily dose.
Persistent withdrawal symptoms throughout despite multiple days of dosing
Suggests the dose is meaningfully below the effective threshold for this subject's tolerance level. Dose escalation is likely needed.
Practical Dosing Summary
Putting the above together into an actionable starting-dose decision framework:
Characterize the prior agonist exposure
This is the most important step. An opioid-naive or low-tolerance subject starts at 5–10 mg. A subject with moderate kratom (7-OH) dependence starts at 15–30 mg. A subject with significant prescription opioid history starts at 30–60 mg. When in doubt, start at the lower end of the relevant range.
Use volumetric solution for sub-20 mg doses
Powder is acceptable for doses above 20 mg where ±1 mg imprecision is a small percentage error. Below 20 mg — and especially below 10 mg — the 10 mg/mL solution is strongly preferred for its sub-milligram resolution.
Split into two daily doses
A split dose (morning and evening) produces more stable receptor occupancy than a single large dose, reduces peak effects, and is easier to taper smoothly. If the total daily dose is 20 mg, take 10 mg twice daily.
Assess response at 48–72 hours before adjusting
SR-17018 may take several doses to establish stable plasma levels and receptor occupancy. Do not adjust the starting dose based on a single administration. Evaluate at 48–72 hours and adjust up by 25–50% if clearly insufficient, or hold if partial response is observed.
Once stabilized, begin taper no sooner than 1–2 weeks
Attempting to taper before the nervous system has adapted to the starting dose accelerates the timeline in a way that tends to produce compensatory withdrawal symptoms. Allow at least 1–2 weeks of stable dosing before beginning dose reduction.
Calculate Your Taper Schedule
The Taper Calculator generates a week-by-week reduction schedule based on your starting dose, target reduction rate, and interval. Outputs are in mL at 10 mg/mL for direct use with the volumetric solution.
Related Research
Volumetric Dosing for Opioid Taper: Why Liquid Beats Powder
Why liquid SR-17018 at 10 mg/mL enables sub-milligram precision impossible with powder — with dose tables and a practical two-phase taper protocol.
Read articleSR-17018 Preclinical Dosing Literature Review
Comprehensive review of SR-17018 dosing data from published preclinical studies — routes, ranges, and observed effects.
Read articleSR-17018 & G-Protein Biased Agonism Explained
Understanding G-protein biased signaling at the mu-opioid receptor and why SR-17018 preferentially activates the G-protein pathway.
Read article